Jeffrey V. Poulton

EVP, Chief Financial Officer

Jeffrey V. Poulton (EVP, Chief Financial Officer) filed 5 Form 4 reports in the trailing twelve months (0 purchases, 5 sales), most often in Alnylam Pharmaceuticals, Inc. (ALNY). The largest single filing was $1.5M of ALNY (3,308 sh across 7 lots, as filed), executed Oct 2 2025.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

–

no purchases on file

Delay-adjustediThe same average, entered at disclosure dates

–

returns measure stock purchases only

Filings, ttm

0 buys · 5 sells

Median delay

–

execution → disclosure

Volume, ttmiDollar value disclosed in the trailing twelve months

$3.4M

shares × price, as filed

Last traded

Mar 4

Filed Mar 6

Median ADV $470.9M across their filed names

Open performance→

Volume by month

Buys $0 Sells $4.5M

Shares × price, as filed · by filing month · past 24 months

Sectors filed on

Healthcare 5 filings

Sector per market data · by filing · past 12 months

Most traded names

ALNY

Alnylam Pharmaceuticals, Inc. ALNY · 0 buys · 7 sells 7 filings

Recent filings

ALNYSALE Alnylam Pharmaceuticals, Inc. View filing → $386K
1,192 sh across 2 lots
Exec Mar 4
Filed Mar 6 · 5:30 PM ET ALNYSALE Alnylam Pharmaceuticals, Inc. View filing → $441K
1,351 sh across 3 lots
Exec Mar 2
Filed Mar 4 · 5:30 PM ET ALNYSALE Alnylam Pharmaceuticals, Inc. View filing → $695K
2,242 sh × $310.08
Exec Feb 13
Filed Feb 17 · 5:30 PM ET ALNYSALE Alnylam Pharmaceuticals, Inc. View filing → $384K
1,054 sh across 3 lots
Exec Jan 12
Filed Jan 14 · 5:30 PM ET ALNYSALE Alnylam Pharmaceuticals, Inc. View filing → $1.5M
3,308 sh across 7 lots
Exec Oct 2 2025
Filed Oct 3 2025 · 5:30 PM ET ALNYSALE Alnylam Pharmaceuticals, Inc. View filing → $823K
1,814 sh across 3 lots
Exec Aug 18 2025
Filed Aug 19 2025 · 5:30 PM ET ALNYSALE Alnylam Pharmaceuticals, Inc. View filing → $238K
945 sh × $251.42
Exec Nov 26 2024
Filed Nov 27 2024 · 5:30 PM ET